Infectious Disease Therapeutics Market Size, Share and Trends 2025 to 2034

Forecast Year, 2034

USD 179.91 Bn

CAGR, 2025 - 2034

3.8%

Report Coverage

Global

What is the Infectious Disease Therapeutics Market Size?

The global infectious disease therapeutics market size accounted for USD 128.61 billion in 2025 and is expected to reach around USD 179.91 billion by 2034, expanding at a CAGR of 3.8% from 2025 to 2034.

Market Highlights

• North America led the global market with the highest market share of 40% in 2024.
• By mode of treatment, the drugs segment has held the largest market share in 2024.
• By target organism, the antibacterial segment captured the biggest revenue share in 2024.
• By infection type, the bacterial infection segment registered the maximum market share in 2024.
• By distribution channel, the hospital segment is estimated to hold the highest market share in 2024.

How Did Outbreak Support the Forecast Development?

Infectious diseases spread from one person to another by indirect or direct contact. For treating infectious diseases medicines which are anti-infective in nature need to be consumed by the patients. These diseases are mainly caused due to pathogens like viruses, bacteria, fungi and parasites. The defense system of the host is acted upon directly with a view to target the organism that is causing the disease and cure is brought into effect. The huge number of people belonging to the geriatric population has emerged as a great opportunity for the growth of the infectious disease therapeutics market.

The outbreak of the and make was an example of an infectious disease which was caused due to coronavirus. The occurrence of this pandemic emerged as a major growth factor for the infectious disease therapeutics market. The huge number of technologically advanced medicines that were launched during the course of the pandemic has helped the market to record a tremendous revenue over the period of time.

Infectious Disease Therapeutics MarketGrowth Factors

The increasing prevalence of infectious diseases in the society has emerged as a major growth factor for the therapeutic system as well. Advanced medicines have been launched by the key market players for treating infectious diseases with a view to produce better profits. Initiatives have been taken by the government for providing advanced facilities to the citizens in order to treat infectious diseases.

A huge number of people who belong to the genetic population has emerged as a major opportunity for the growth of the market. A rise in the disposable income available with the people has emerged as a major opportunity as well. A high disposable income enables the people to opt for advanced treatment options which helps the growth of the market.

Insurance companies are providing attractive reimbursement policies that are supporting the expenses of the people and hence they are opting for better treatment options to get themselves treated in a shorter period of time. The extensive research and development programs carried out by the key market players with a view to introduce modern medicines into the society has help the market to record a considerable revenue over the period of time.

• Increasing number of cases suffering with infectious diseases
• Government initiatives to enhance health care system
• Attractive reimbursement policies
• Huge number of people belonging to geriatric population
• Increasing disposable income available with the people
• Modern medicines introduced by key market players

Infectious Disease Therapeutics Market Outlook:

• Global Expansion: A rise in HIV, hepatitis, tuberculosis, malaria, and other cases, as well as the expansion of mRNA technology, immunotherapies, and nanotechnology-based delivery systems, are boosting the overall transformation.
• Major Investor: Giant companies, such as Pfizer, GSK, and Gilead Sciences, are widely investing in innovation in areas like antiviral, antifungal, and antibiotic treatments.
• Startup Ecosystem: In October 2025, French startup Exeliom Biosciences expanded funding with €2.85 million to raise immunotherapy for cancer.

Market Scope

Market Dynamics

Drivers

• Increasing prevalence of diseases among the people- the number of people who are suffering with infectious disease has increased tremendously over the period of time what is resulting from the low immunity system possessed by them which is the after effect of the faulty food habits and sedentary lifestyle practiced by them. An improper lifestyle hampers the immunity power of the person and hence they tend to acquire infectious diseases more commonly as compared to the earlier period.
• Increasing prevalence of antiviral drugs- The increasing consumption of antiviral drugs by the people which is dispensed over the counter shows an immediate effect on the body of the individual but hampers the immunity system to a great extent as it does not let the body to fight against the disease pathogens on its own which makes the system of the body weak and fragile.
• Government initiatives- the active steps taken by the government to support the health care system by providing modern facilities to the people has boosted the market for infectious disease therapeutics to a great extent by attracting the potential consumers over the period of time.

Challenges

• High cost of treatment- the high cost associated with the treatment of infectious diseases with technologically advanced medicines challenges the growth of the market to a great extent as it imposes an additional pressure on the disposable income of the people. The increasing demanding supply of generic drugs in the market has also challenged the growth of the branded drugs which treat infectious diseases.
• Lack of skilled professionals- a major challenge which is faced by the infectious disease therapeutics market is the shortage of skilled professionals in the sector which hampers the growth of the market to a great extent.

Opportunities

• Increasing acceptance to advanced mode of treatments- people all over the world are accepting the use of modern medicines which are technologically advanced which is helping the infectious disease therapeutics market to show a tremendous growth over the over the period of time and provides a great opportunity to the growth of the market.
• Disposable income- the presence of higher disposable income available with the people enables them to purchase the technically advanced medicines which show a faster effect on the body and helps to restore health in a shorter period of time. This emerges as a major opportunity for the growth of the market.
• Attractive reimbursement policies- various initiatives taken by the government to support the healthcare system by providing attractive reimbursement policies to the people through insurance companies has encouraged people to opt for technically advanced treatment options which has emerged as a major opportunity for the growth of the market.

Segments Insights

Mode of Treatment Insights

On the basis of the mode of treatment, the segment of drugs has emerged as the fastest-growing market owing to its largest share in the global economy. Increasing demand for advanced drugs in the market has helped in this segment to record a considerable revenue over the period of time and it's foreseen to continue its growth in a similar fashion during the future as well. The huge number of people belonging to the geriatric population has emerged as a major opportunity for the segment of drugs as it is the most common line of treatment opted by these people. The availability of medicines over the counter has also proved to be a major opportunity for the growth of the drug segment. Increasing disposable income available with the people has enabled them to opt for advanced drugs available in the market for the purpose of treatment. The other segment which has been discussed under this category includes vaccines which has become a common entity after the birth of a child to the period up till when new diseases keep on emerging into the market along with their vaccinations.

Target Organism Insights

On the basis of the target organism, the segment of antibacterial has emerged as the largest market due to its significant share in the global economy. The contribution of the anti-bacterial segment is expected to grow further at a faster rate during the future as well. The increasing prevalence of diseases which spread through the mode of bacteria has boosted the market for the antibacterial segment to a great extent. Increasing prevalence of diseases such as hepatitis A, influenza, tuberculosis, HIV and hepatitis C Merged as a major opportunity for the growth of the anti-bacterial segment in the current market. Increasing disposable income available with the people has emerged as a major opportunity for the sales and demand of advanced antibacterial drugs in the market.

Infection Type Insights

On the basis of infection type, the segment of bacterial infection has emerged as the fastest growing market over the period of time and is expected to show a tremendous boost during the future period as well. The increasing research and development programs conducted by the key market players with a view to introduce innovative medicines that are technologically advanced has helped the segment of bacterial infection to record a considerable growth over the period of time. The huge number of people who suffer with bacterial infection has also emerged as a major opportunity for the growth of the market. The weekend immunity system of the people provides a great opportunity for the bacteria to spread the infectious diseases and hence a considerable growth is recorded over the period of time.

Distribution Channel Insights

On the basis of distribution channel, the segment of hospitals has emerged as the fastest growing market as it proves to be the primary center where a patient shows up first when they are infected buy an infection and hence this sector has recorded a considerable revenue over the period of time. The huge number of people visiting the hospital sector on a daily basis for treating infectious diseases has also proved to be a major growth factor for the market. Dream basement policies and other facilities provided by the hospital sector through the insurance companies emerges as an attractive opportunity for the growth of the market. A number of different facilities are available in the hospital sector which prevents the patient from running to different centers which emerges as another opportunity for the growth of the market.

Regional Insights

U.S. Infectious Disease Therapeutics Market Size and Growth 2025 to 2034

The U.S. infectious disease therapeutics market size is estimated at USD 16.54 billion in 2025 and is predicted to be worth around USD 51.55 billion by 2034, at a CAGR of 4% from 2025 to 2034.

Exceptional mRNA Technology Advances: US Market Trend

The US market has been pushing prospective progression by developing advanced mRNA technology, which is increasingly used in shingles, HIV, tuberculosis, and malaria, with many candidates in early-stage clinical trials. Additionally, many players are leveraging bacteriophage therapy for a specific target and to kill bacteria.

How did North America Dominate the Market in 2024?

On the basis of geography, the region of North America has emerged as the largest market for infectious disease therapeutics pertaining to the increasing prevalence of infectious diseases in this region. North America accounted highest revenue share 40% in 2023. The huge number of people belonging to the geriatric population in this region has become a major growth factor for the infectious disease therapeutics market. Higher disposable income available with the people has also emerged as a major growth factor for the market. Advanced health care facilities provided by the government in the form of reimbursement policies has supported the growth of the market to a great extent.

Surging Expansion of Diverse mRNA Facilities is Propelling the Asia Pacific

A growing incidence of a variety of infectious diseases among the ASAP population, especially in China and India, is further encouraging the growth of advanced vaccine facilities in different regions. Such as in 2024, Sanofi opened a $595 million vaccine facility to manufacture millions of doses annually for pandemic response. Meanwhile, Moderna also inaugurated a state-of-the-art facility in Victoria in December 2024 for mRNA vaccine production.

The next region which has shown a tremendous growth is that of Asia Pacific which accounts for a considerable share in the global market for infectious disease therapeutics. The European region has also shown a considerable growth over the period of years.

Accelerating Focus on Neutralizing Antibodies: China Market Trend

The infectious disease therapeutics market in China is driven by the rise of neutralizing antibodies for numerous concerns. Specifically, a combination therapy called Amubarvimab/Romlusevimab (BRII-196 and BRII-198) of neutralizing antibodies from Brii Biosciences received approval in China for pre-exposure and post-exposure prophylaxis, also in treatment for mild to moderate COVID-19 patients.

Emergence of EMA Recommendation is Assisting Europe

Europe, with a lucrative growth in the market, is particularly fueled by the expanding EMA has recommendation for a new mRNA vaccine against lower respiratory tract disease caused by RSV (Kostaive) and many others (Pfizer's Abrysvo and GSK's Arexvy) for use in older adults. Moreover, the EMA further authorized the first vaccine to protect individuals aged 12 years and older against the Chikungunya virus.

Promoting Substitutes to Antibiotics: German Market

Recently, DZIF scientists have been evolving plans for eliminating multidrug-resistant bacteria, an urgent global health concern. This prominently comprises the use of antibodies against Pseudomonas aeruginosa virulence factors and genetically developed phage lysins and bacteriocins to eliminate hospital germs, like Staphylococcus aureus.

Infectious Disease Therapeutics Market: Value Chain Analysis

• R&D: The market is exploring new vaccines, drugs, and diagnostics through a global network of alliances among academia, industry, and government.
  Key Players: Moderna, BioNTech, Bavarian Nordic, etc.
• Clinical Trials & Regulatory Approvals: This mainly encompasses a structured process of clinical trials overseen by key regulatory bodies, often using rapid pathways due to public health needs.
  Key Players: Centre for Infectious Disease Research in Zambia, Ina-Respond, National Institute of Allergy and Infectious Diseases (NIAID), etc.
• Patient Support & Services: This leverages comprehensive programs powered by pharmaceutical companies, healthcare providers, and advocacy groups to assist patients in managing their condition and adhering to their treatment plans.
  Key Players: ProPharma, Medapp, WellaHealth, etc.

Key Companies and Their Offerings & Contributions in the Market

• Pfizer: Advances antivirals, strengthens vaccine R&D, and expands its infectious-disease portfolio through strategic acquisitions, improving global treatment and prevention capabilities.
• GlaxoSmithKline:Provides a broad vaccine range, HIV therapies, and effective antivirals, significantly enhancing global infectious-disease prevention and therapeutic access.
• Merck & Co.: Delivers strong vaccine programs, develops new antimicrobials, and forms strategic partnerships to widen innovative infectious-disease treatment options.
• F. Hoffmann-La Roche: Combines advanced diagnostics with targeted therapies, enabling early detection and personalized management of major infectious diseases.
• AstraZeneca: Innovates in respiratory vaccines, expands through acquisitions, and collaborates globally to strengthen infectious-disease prevention and treatment solutions.

Recent Developments

• In March 2021 - with a view to understand the mutations of the coronavirus in detail Cobas SARS-CoV-2 Variant Set 1 assay was introduced by Roche Diagnostics.

Segments Covered in the Report

By Mode of Treatment

• Vaccines
• Drugs

By Target Organism

• Antifungal
• Antiviral
• Antibacterial
• Anti-parasite
• Others

By Infection Type

• Viral
• Parasitic
• Fungal
• Bacterial
• Others

By Distribution Channel

• Clinic
• Hospitals
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa